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Aim: SNPs in the gene for TPMT exemplify one of the most successful translations of pharmacogenomics
into clinical practice. This study explains the correlation between common SNPs and variable number of
tandem repeats (VNTR) in promoter of the gene. Materials & methods: We determined VNTR polymor-
phisms, as well as TPMT*2 and TPMT*3 SNPs and TPMT activity in Slovenian and Italian individuals and
lymphoblastoid cell lines. Results:We observed a previously unreported VNTR allele, AB7C, in a TPMT*3A
heterozygous individual. VNTRswith two (AB2C) and three ormore (ABnC, n≥ 3) Bmotifs were statistically
significant in complete linkage disequilibrium (D′ = 1, r2 = 1, p < 0.0001) with the TPMT*3C and TPMT*3A
alleles, respectively. Conclusion: The study provides insights into the stepwise evolution of TPMT*3 alleles
from *3C to *3A, with increasing number of B motifs in the VNTR region.
Graphical abstract:
AB2C
AB3C
AB4C
AB5C
AB7C
CBB
A
TPMT*3C
TPMT*3B
Haplo type
 
Exon
 10
Exon 7VNT
R reg
ion
B +
B +
B +
B +
CB B
B
A
CB B B
B
A
CB B B B
B
A
CB B B
B B B
B
A
TPMT gene
E
vo
lu
tio
n 
of
 V
N
T
R
 p
at
te
rn
s
TPMT
*3A
First draft submitted: 23 July 2018; Accepted for publication: 24 September 2018; Published online:
22 October 2018
Pharmacogenomics (Epub ahead of print) ISSN 1462-241610.2217/pgs-2018-0123 C⃝ 2018 Future Medicine Ltd
Research Article Urbancˇicˇ, Sˇmid, Stocco, Decorti, Mlinaricˇ-Rasˇcˇan & Karas Kuzˇelicˇki
Keywords: acute lymphoblastic leukemia • genetic polymorphisms • inflammatory bowel disease • linkage disequi-
librium • lymphoblastoid cell lines • thiopurine S-methyltransferase • TPMT activity • TPMT • variable number of
tandem repeats • VNTR
Due to high correlation of its activity with common genetic polymorphisms, TPMT exemplifies one of the
most successful translations of pharmacogenomics into clinical practice [1]. TPMT plays an important part in the
deactivation pathway of thiopurine drugs by directing conversion of thiopurines, 6-mercaptopurine (6MP) and
6-thioguanine, to the methylated entities, 6-methyl-MP (6MMP) or 6-methylthioguanine, respectively [2]. This S-
adenosylmethionine-dependent methylation decreases levels of 6-thioguanine nucleotides, the active metabolites of
thiopurine drugs, which are used in patients with acute lymphoblastic leukemia (ALL), transplantation procedures
and autoimmune disorders [3–5]. The population distribution of TPMT activity is trimodal [2]. The majority of
individuals (89%) have normal TPMT activity, around 11% of population have decreased activity and around
0.3% bears completely deficient enzyme [6]. Often, the decrease in TPMT activity is due to SNPs in the TPMT
gene, among which TPMT*3A, TPMT*3C and TPMT*2 are the most common [7]. Individual genetic variability
of TPMT is mirrored in levels of 6-thioguanine nucleotides. When patients with lower enzyme activity are treated
with standard thiopurine doses, they exhibit a lower relapse rate, but are more prone to severe hematologic side
effects [3,8].
In addition to the variability caused by SNPs in the coding region of TPMT, its G/C rich promoter is variable as
well, containing DNAmotifs in the form of a variable number of tandem repeats (VNTR) [9]. This repetitive DNA
region consists of three motifs in its internal structure, named A, B and C (Figure 1) [10]. Reported human VNTR
alleles are made up of 1–7 repeats of motif A, 1–6 repeats of motif B and a single motif C. The motifs always appear
in the same order: AmBnC [10]. The overall length of repeats ranges from three to nine motifs, which classifies
VNTR alleles in the TPMT promoter as minisatellites [11]. The evolutionary mechanism, that best describes the
formation of novel VNTR alleles in the TPMT promoter, is the stepwise mutation model (SMM) [12,13]. The
model assumes gradual gaining (or losing) of one single motif at the time, explaining the phylogenetic relationships
between VNTR alleles [13].
Early studies attempted to determine the influence of VNTRs in the TPMT promoter on TPMT enzyme
activity. Lower activity of the enzyme was associated with VNTR genotypes containing more than five repeats in
total [9,14,15]. However, several of these studies did not take into account the structure of the VNTR region (i.e., the
exact number of A and B motifs), or did not label the alleles consistently, preventing exact conclusions. Recently,
the number of A motifs in VNTR has been negatively correlated with the transcription rate of TPMT [16,17]. The
results have been replicated in a clinical trial on patients treated with thiopurines [18], suggesting the importance of
precise characterization of VNTR patterns in terms of the number of A and B motifs for clinical applications.
The function and the mechanism of action of the VNTR region remain unknown. In this study, we investigated
the association of VNTR architecture with TPMT activity and its connection to common clinically relevant
genetic polymorphisms in the TPMT gene. We sequenced the TPMT promoter, genotyped TPMT for TPMT*2
and TPMT*3 alleles and measured TPMT activity in healthy Slovenian volunteers. Results were validated in
a cohort enriched for variant TPMT*3 alleles, comprising nonrandomly selected Italian patients with ALL or
inflammatory bowel disease (IBD) and lymphoblastoid cell lines (LCL) from healthy Israeli and Estonian donors.
Materials & methods
Blood samples
Venous blood (3–5 ml) from 132 unrelated healthy Caucasian volunteers from Slovenia [6] was used for TPMT
genotyping. TPMT activity was measured in the red blood cells (RBC) of 29, randomly chosen, Slovene individu-
als [6]. Since the frequency of TPMT*3 alleles in the Slovenian cohort was too low to properly perform the linkage
disequilibrium (LD) analysis, randomly selected Slovenian cohort was complemented by the samples of individuals
previously determined to be carriers of TPMT*3 alleles. For VNTR analysis 24 such samples were nonrandomly
selected from Italian ALL or IBD patients [19,20].
Lymphoblastoid cell lines
In order to further enrich the study cohort with TPMT*3 alleles, we conducted experiments on 41 LCLs of
consenting healthy adults, 30 of which were obtained from the National Laboratory for the Genetics of Israeli pop-
ulations, Tel-Aviv University, Israel [21]. LCLs from the National Laboratory for the Genetics of Israeli populations
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Figure 1. The structure of variable number of tandem
repeats in TPMT.The sequence of A, B and C VNTR motifs
and location of *3 polymorphisms in the coding region
of TPMT are shown.
Table 1. The list of analyzed SNPs in the TPMT coding region, their rs numbers, nucleotide changes and TaqMan Assay IDs.
rs number Allele symbol Nucleotide change TaqMan Assay ID
rs1800462 TPMT*2 238G !C C 12091552 30
rs1800460 TPMT*3B 460G !A C 30634116 20
rs1142345 TPMT*3C 719A !G C 19567 20
were generated from the lymphocytes of 30 healthy donors – 27 Ashkenazi individuals, 2 Palestinian individuals
and 1 Ethiopian individual as previously described [21]. The other 11 LCLs were prepared from the lymphocytes
of selected Caucasian subjects from the Estonian Biobank, Estonian Genome Center, University of Tartu [22].
The lymphocytes of healthy adult donors were immortalized in vitro by Epstein–Barr virus. Cells were cultured
in RPMI medium (Merck, Sigma-Aldrich, Darmstadt, Germany), supplemented with 10% fetal bovine serum
(Thermo Fisher Scientific, Gibco, MA, USA), 4mM l-glutamine and antibiotics (100 U/ml penicillin; 100 µg/ml
streptomycin; 250 ng/ml amphotericin B; all from Merck, Sigma-Aldrich) and kept under humidified conditions
at 37◦C and 5% CO2 [21].
Extraction of DNA and genotyping
For blood samples, the extraction of DNA and determination of TPMT*2 and TPMT*3 alleles has been described
previously [6,19,20].
For LCLs, DNA was extracted from 2.5 × 106 cells according to the manufacturer’s instructions using the
QIAamp DNA Blood Mini Kit (Qiagene, Venlo, The Netherlands). TPMT*2 and TPMT*3 alleles were deter-
mined in samples with 10 ng of DNA using TaqMan SNP Genotyping Assay (Thermo Fisher Scientific, Applied
Biosystems) on a Roche LightCycler 480 system, following the manufacturers’ instructions. SNPs and part numbers
of all TaqMan SNP Genotyping Assays are listed in Table 1.
The promoter region of TPMT was genotyped for VNTR in the DNA isolated from both, blood samples
and LCLs. The region of interest was amplified using primers F (5´-GTCACCCGAAATCCGCCAC-3′) and R
(5′-CGTTCCCTTTCTCACCCGC-3′) with the PCR reaction mix containing 80–160 ng of DNA per sample.
PCR reagent from FIREPol DNA Polymerase, PCR kit, with 30% Solution S for GC rich regions (i.e., G/C
rich enhancer; all from Solis BioDyne, Tartu, Estonia) was used according to the manufacturer’s instructions. The
following thermal cycling conditions were applied: 15 min 95◦C, 30× (1 min 95◦C, 30 s 58◦C, 1 min 72◦C),
8 min 72◦C and cooling. The presence of PCR fragments containing 622–730 base pairs was confirmed by gel
electrophoresis composed of 2% agarose with 1× SYBR safe DNA gel stain (Thermo Fisher Scientific, Invitrogen).
The separation of fragments was performed at 100 V and 400 A and lasted 20 min. PCR products were purified by
QIAquick PCR purification Kit (Qiagene, Venlo, The Netherlands) according to the manufacturer’s instructions.
Samples were sequenced by McLab (CA, USA).
TPMT activity assay
TPMT activity in blood samples of 29, randomly chosen, healthy individuals was measured as previously de-
scribed [6].
Activity of the enzyme in LCLs was measured by the reversed-phase HPLC method [6,23]. Briefly, 10 × 106
cells were resuspended in 150 mM potassium-phosphate buffer, pH 7.4, and lysed by sonication. An aliquot of all
samples was taken from the lysates for determination of proteins. The amount of produced 6MMP was measured
in the rest of the cell lysate after 2-h incubation with 50 µM S-adenosylmethionine and 2.25 mM 6MP on 37◦C.
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Table 2. Frequency of TPMT*3 genotypes in a cohort of randomly selected healthy Slovenian individuals and in the
cohort enriched for TPMT*3 alleles.
Genotype Randomly selected Slovenian individuals Cohort enriched for TPMT*3 alleles†
n Frequency n Frequency
*3A/*3A / / 1 0.024
*3A/*3C / / 1 0.024
*1 /*3A 11 0.083 32 0.268
*1 /*3C 1 0.008 2 0.024
*1 /*1 120 0.909 29 0.659
Total 132 65
†Nonrandomly selected samples: lymphoblastoid cell lines from Estonian and Israeli donors (n = 41) and blood samples from Italian inflammatory bowel disease or acute lymphoblastic
leukemia patients (n = 24).
Table 3. Allele frequencies of variable number of tandem repeats in the present and previous studies.
VNTR† pattern Frequency of VNTR alleles
Slovenian cohort
(n = 132) (present
study)
Serbian ALL cohort
(n = 57)
Serbian cohort
ALL + normal (n
= 154)
Portuguese cohort
(n = 176)
Mozambique
cohort (n = 88)
Asian British cohort
(n = 85)
A2BC *4a 0.439 0.535 0.542 0.447 0.506 0.482
A2B2C *5a 0.386 0.325 0.3 0.357 0.193 0.271
A2B3C *6a 0.087 0.053 0.075 0.096 0.034 0.147
AB4C *6b 0.019 0 0.003 0.003 0 0
A5BC *7a 0.015 0.053 0.036 0.056 0.102 0.029
AB5C *7b 0.015 0 0.003 0.006 0 0
A4BC *6c 0.008 0 0.003 0 0 0.006
A6BC *8a 0.008 0 0.003 0.025 0.051 0.012
A2B5C *8b 0.008 0 0 0 0.011 0
ABC *3 0.004 0 0 0.003 0.017 0
AB2C *4b 0.004 0.018 0.007 0.003 0.006 0.012
AB3C *5c 0.004 0.009 0 0 0.023 0
A3B2C *6d 0.004 0 0.016 0 0 0
A7BC *9(a) 0.004 0 0 0 0 0.029
AB7C 0.004 0 0 0 0 0
A3BC *5b 0 0.009 0.01 0.006 0.028 0.006
A2B4C *7c 0 0 0 0 0.017 0
A2B6C *9(b) 0 0 0 0 0.006 0
A4B2C *7c 0 0 0 0 0 0.006
†Regarding the terminology of VNTR alleles, we used the nomenclature ABC instead of for example *5b, since this classification is more informative and transparent. However, both
versions are specified in Table 3, allowing for comparison with previous studies.
Data was taken from the following sources: Serbian ALL cohort [18]; Serbian cohort ALL + normal [16]; Portuguese cohort [12]; Mozambique cohort [12]; Asian British cohort [26].
ALL: Acute lymphoblastic leukemia; VNTR: Variable number of tandem repeats.
Total protein concentration was determined using the BioRad Protein Assay Kit (Bio-Rad, CA, USA), in accordance
with the manufacturer’s instructions. The activity was calculated as the amount of 6MMP produced in an hour
per mg of protein. The mean TPMT activity for each individual was obtained from at least three independent
experiments.
Statistical methods
Sequences were determined using Finch TV software (Geospiza, Inc., WA, USA; http://www.geospiza.com).
LD: since SNPs and VNTRs were determined separately, we first performed an analysis to estimate the haplotypes
using PHASE platform for Windows 2.1.1 [24,25], which allowed for preservation of VNTR architecture in its
original form. Motifs A and B were assigned as two separate alleles in the immediate vicinity of one another (1 bp).
Standardized LD (D′) was then calculated from the estimated haplotype frequencies individually for each VNTR
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Figure 2. Allele frequency distribution diagrams for randomly and nonrandomly selected cohorts.
†Nonrandomly selected samples: lymphoblastoid cell lines from Estonian and Israeli donors (n = 41) and blood samples
from Italian inflammatory bowel disease or acute lymphoblastic leukemia patients (n = 24).
‡Variable number of tandem repeats (VNTR) alleles with frequency lower than 2%: AB4C (1.89%), AB5C and A5BC
(1.52%), A4BC and A6BC (0.76%), ABC, AB2C, AB3C, AB7C, A7BC and A3B2C (0.38%).
§VNTR alleles with frequency lower than 2%: A6BC and ABC (1.54%), A4BC and A2B5C (0.77%).
allele in combination with each SNP (*1, *3C, *3A [*3B]) (Table 4). The target VNTR allele was compared
against a pool of other VNTR alleles. VNTR minisatellites have a significantly higher recombination rate than
SNPs. Thus, SNPs can persist in all VNTR alleles formed in subsequent evolutionary steps. When addressing LD
between VNTR patterns and TPMT*3A allele, we therefore merged haplotype information of samples containing
VNTR alleles with ABnC, n >2 and compared them against a pool of other VNTR alleles. The significance of
calculated LD was then determined by χ2 test.
It is noteworthy that the analysis of the VNTR region and SNP genotype analyses were performed separately by
two researchers in a double-blind manner, to avoid bias. Neither of the researchers knew results on the genotype of
the regions prior to the conclusion of the data analysis.
Results
Frequency of TPMT*3 & VNTR alleles
To evaluate the genetic background of TPMT in each individual, we first genotyped 132 randomly selected, healthy
Slovenian blood donors for polymorphisms in coding regions and promoter of TPMT. The allele frequencies of
TPMT*3A andTPMT*3C resembled those in otherCaucasian populations.However, noTPMT*3A andTPMT*3C
homozygous individuals were detected (Table 2). Furthermore, no TPMT*2 alleles were found in the Slovenian
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Figure 3. Phylogenetic associations between different alleles of variable number of tandem repeats in TPMT and
their frequency distribution in the present set of Slovenian individuals, designated by the diameter of circles. !
signifies other possible variable number of tandem repeats alleles, found in lymphoblastoid cell lines or previously
reported by other studies [12,16].
Table 4. Linkage disequilibrium for all combinations of variable number of tandem repeats and SNPs in TPMT, obtained
from estimated haplotype combinations.
Allele VNTR Allele ORF D′ r2 !2 p-value
ABC *1 1.000 0.001 0.439 0.507
AB2C *3C 1.000 1.000 396.000 "0.0001*
AB3C *3A 1.000 0.078 30.726 "0.0001*
AB4C *3A 1.000 0.469 185.725 "0.0001*
AB5C *3A 1.000 0.362 143.417 "0.0001*
AB7C *3A 1.000 0.019 7.623 0.006*
A2BC *1 1.000 0.092 36.541 "0.0001*
A4BC *1 1.000 0.001 0.442 0.506
A5BC *1 1.000 0.003 1.345 0.246
A6BC *1 1.000 0.001 0.590 0.442
A7BC *1 1.000 0.000 0.146 0.702
A2B2C *1 1.000 0.076 30.001 "0.0001*
A2B3C *1 1.000 0.014 5.436 0.020*
A3B2C *1 1.000 0.000 0.146 0.702
ABnC; n ! 2 *3A 1.000 1.000 396.000 "0.0001*
not ABnC n ! 1 *1 1.000 1.000 396.000 "0.0001*
Number of individuals: 197 (Slovenian cohort, lymphoblastoid cell lines and patients with acute lymphoblastic leukemia or inflammatory bowel disease). Significance (p) was calculated to
one degree of freedom.
*Statistically significant linkage disequilibrium.
D′: Normalized linkage disequilibrium; r2: Correlation coefficient; VNTR: Variable number of tandem repeats.
cohort. We determined 14 different VNTR alleles generating 24 different VNTR genotypes in this cohort. In
accordance with previous studies, the most frequent allele was A2BC (43.1%), followed by A2B2C (37.9%) and
A2B3C (8.5%) (Figure 2 & Table 3). All other alleles were represented at frequencies of less than 2% in the
population. The most common genotypes were, as expected, A2BC/A2B2C (37.3%), A2BC/A2BC (17.9%) and
A2B2C/A2B2C (14.2%). Interestingly, the VNTR allele AB2C was present only in the individual with allele
TPMT*3C. Moreover, all TPMT*3A individuals carried one of the following VNTR alleles: AB3C, AB4C, AB5C
and AB7C. None of these VNTR alleles (ABnC, n ≥2) were present in wild-type individuals. To our knowledge,
the VNTR allele AB7C was observed for the first time.
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Figure 4. Activity of TPMT in relation to TPMT*3 and alleles of variable number of tandem repeats. (A) Distribution
of TPMT activity according to TPMT*3 genotype in Slovenian individuals. (B) Classification of TPMT activity based on
TPMT genotype in lymphoblastoid cell lines (LCLs). Groups of LCLs with different TPMT*3 genotype significantly differ
in TPMT activity (p = 0.0001). (C) and (D) TPMT activity of healthy Slovenian individuals and LCLs, respectively, in
relation to the number of repeats in the VNTR pattern. TPMT activity trend with the total number of repeats is
represented by ◦, solid line, while the trend of only wild-type (*1 /*1 ) individuals and LCLs is shown by !, dashed line.
(E) Distribution of TPMT activity of LCLs across the groups with different VNTR patterns. LCLs carrying at least one
TPMT*3 allele are shown in darker purple. Pooled subgroups of variable number of tandem repeats motifs
(i.e., AmBC, ABnC and A2BnC) exhibited statistically significant differences in TPMT activity (p = 0.0001). Results are
presented as median ± interquartile difference.
*p = 0.0001.
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As the frequency of TPMT*3 alleles in the random population is too low to convincingly confirm the association
between TPMT*3 and VNTR alleles, we next selected additional samples from individuals previously determined
to carry TPMT*3 allele(s). Additionally, a few samples of wild-type TPMT individuals were added. These samples
originated from IBD or ALL patients (n = 24) and from LCLs obtained from Estonian and Israeli donors (n =
41). By combining samples from LCLs, IBD and ALL patients, we intentionally created a cohort with elevated
frequency of TPMT*3 alleles (Table 2 & Figure 2). DNA was extracted from 2 TPMT*1/*3C heterozygous, 32
TPMT*1/*3A heterozygous, one homozygous and one mixed heterozygous (*3A/*3A and *3A/*3C), as well as 29
wild-type individuals, and TPMT*3 genotype was reconfirmed (Table 2). The sequencing of the TPMT promoter
region determined 12 structurally different VNTR alleles in this TPMT*3 enriched cohort (Figure 2).
In all three cohorts combined (healthy Slovenian, Italian ALL and IBD patients and LCLs), AB3C, AB4C,
AB5C and AB7C patterns were detected only in individuals with at least one TPMT*3A allele. Furthermore, the
individual with genotype *3A/*3A was also AB4C/AB4C homozygous at the VNTR locus. These results suggest
that TPMT*3A allele is in linkage with ABnC (n ≥3) VNTR patterns and corroborate results from Slovenian
population study. In all three cohorts, AB2C was detected in individuals with *1/*3C and *3A/*3C genotypes.
The latter had AB4C/AB2C genotype at the VNTR locus. Since AB4C associates with the TPMT*3A allele, the
data further suggest that the TPMT*3C allele corresponds to AB2C VNTR motif. The high percentage of ABnC
alleles in the cohort enriched for TPMT*3 variants (Figure 2) confirmed the association between VNTR motifs
AB2C and ABnC (n ≥3) and TPMT*3C and TPMT*3A alleles, respectively.
Evolutionary linkage of VNTR & TPMT*3 polymorphisms
To statistically evaluate the correlation between TPMT*3 and VNTR alleles, we performed an analysis of LD,
which further confirmed our hypothesis. Genotype data of merged samples from the Slovenian cohort, LCLs, ALL
and IBD patients were used to estimate the haplotypes, and calculate the LD and its level of significance (Table 4).
VNTR polymorphism AB2C was in statistically significant complete LD with TPMT*3C polymorphism (D′ = 1,
r2 = 1; p < 0.0001), and pooled polymorphisms AB3C, AB4C, AB5C and AB7C were in complete LD with
TPMT*3A polymorphism (D′ = 1, r2 = 1; p < 0.0001). Other VNTR patterns were in statistically significant LD
with wild-type (TPMT*1) allele (Table 4).
All TPMT*3 alleles occur with VNTR pattern ABnC, where n is at least two. Therefore, we investigated the
evolutionary basis for such an association. TPMT*3A allele is a haplotype that contains TPMT *3C and TPMT
*3B SNPs in a coding region of TPMT (Figure 1) [27]. TPMT*3C allele is quite common, especially in populations
of African origin [28,29]. Meanwhile, TPMT *3B allele almost never occurs separately from TPMT*3C [30,31]. In all
analyzed samples, TPMT *3C allele was present together with VNTR polymorphisms ABnC with two B motifs
(n = 2) andTPMT*3A allele co-existed with the same VNTR patterns that contained three or more Bmotifs (n>2).
Assuming a stepwise mutation model as an evolutionary description of VNTR formation and their phylogenetic
evaluation [12], we hypothesize that TPMT*3C variation occurred concurrently with the AB2C polymorphism
(Figure 3). In further evolutionary genetic changes, an additional B motif in the VNTR region was gained. At
that time, the TPMT*3B mutation appeared, creating the TPMT*3A haplotype, suggesting that the TPMT*3B
variation occurred sequentially after TPMT*3C and not in parallel or separately from it. Since the mutation rate
of VNTR polymorphisms is significantly higher compared with the mutation rate of variations resulting in SNPs,
TPMT*3A was retained, while the VNTR region gained additional B motifs, generating several haplotypes with
TPMT*3A and VNTR ABnC polymorphisms (Figure 3).
Influence of TPMT*3 & VNTR alleles on the TPMT activity
To evaluate whether VNTR polymorphisms affect TPMT activity, we measured the basal activity of the enzyme
in 29 of 132 healthy Slovenian volunteers and in 38 of 41 LCLs. Median TPMT activity of Slovenian donors with
wild-typeTPMT genotype (*1/*1) was 16.6 pmol 6MMP/h/107 RBC,whereas themedian activity of heterozygous
(*1/*3) individuals was 10.0 pmol 6MMP/h/107 RBC (Figure 4A). Due to the low frequency of TPMT*3 alleles
in the randomly selected population, the size of the Slovenian cohort was too small to allow the statistical analysis
of TPMT activity distribution (Figure 4A). However, the activity of two heterozygous individuals was in the
range of previously reported intermediate TPMT activities in the Slovenian and other populations [6,32,33]. The
broad distribution of activities in individuals with wild-type TPMT is also in accordance with several previously
published studies [1,34]. TPMT activity, measured in LCL lysates, significantly correlated with the number of
TPMT*3 alleles (p < 0.0001; Figure 4B). LCLs with wild-type TPMT (*1/*1) had the highest activity (median
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137.4 pmol 6MMP/h/mg prot.), heterozygous LCLs (*1/*3) an intermediate level of activity (median 56.2 pmol
6MMP/h/mg prot.) and variant homozygotes (*3/*3) had the lowest TPMT activity (5.73 pmol 6MMP/h/mg
prot.).
In accordance with previous studies [9,14], we observed a decrease in median TPMT activity with an increase in
the number of repeats in both alleles, irrespective of the number of A and B motifs (Figure 4C&D, solid line). The
same trend of decreasing TPMT activity with the number of VNTR motifs was absent in only wild-type (*1/*1)
individuals and LCLs (Figure 4C & D, dashed line). In addition, we noticed a trend of fewer LCLs with *1/*1
genotype within the groups with more than ten tandem repeats, suggesting that individuals with variant TPMT*3
allele also have longer VNTR region. Not only the total number of tandem repeats, but also their VNTR patterns
(i.e., number of A and B motifs) were associated with TPMT activity (Figure 4E). ABnC patterns had significantly
lower enzyme activity compared with A2BnC (p < 0.0001) and AmBC (p < 0.0001) patterns (Figure 4E).
Discussion
The present study finds that there is a LD between VNTR patterns with ABnC structure (n ≥2) and TPMT*3
alleles. Specifically, motif AB2C is associated with TPMT*3C and ABnC (n ≥3) motifs with TPMT*3A allele.
Furthermore, we identified a previously unreported VNTR pattern AB7C. The individual with this pattern is a
carrier of TPMT*3A allele. Further functional studies for this individual (e.g., the analysis of TPMT activity) could
not have been performed, as we have not been able to obtain the red blood cell sample from this individual.
Our data are strongly supported by other studies. The most demonstrable linkage disequilibria observed in
previous studies were between TPMT *3A and AB4C (*6b), and between TPMT *3C and AB2C (*4b) [26]. In
that study all individual subjects (who originated from Pakistan and India) had only the AB2C VNTR pattern: no
other ABnC polymorphisms were detected [26]. This is in accordance with the distribution of TPMT*3 alleles in the
ethnic groups of Asia [35]. In another study, which assessed a Mozambican population, VNTRmotifs AB4C (*V6b)
and AB5C (*V7b) were absent, while AB2C motif was present; in this population TPMT*3C is the prevalent allele
and TPMT*3A is rare [12]. This is in line with our results and in accordance with the distribution of these variants in
populations of African and Asian origin [12]. Furthermore, VNTR*6, which could represent either AB4C, A4BC or
A2B3C motifs, has been linked to the TPMT *3A polymorphism in early studies of VNTR alleles in TPMT [9,12].
Unfortunately, the information on qualitative structure of VNTR polymorphisms was lacking at that time, making
it impossible to determine which of the three VNTR patterns was in linkage with TPMT*3A allele. Based on these
findings, we can predict that African population would have extremely low frequencies of ABnC, n ≥3, alleles but
higher frequency of AB2C allele, compared with the Caucasian population. Populations of Asian origin have a low
frequency of TPMT*3C and an even lower frequency of TPMT*3A [35,36]. Therefore, AB2C with similar frequency
to the Caucasian population and low frequency of ABnC, n ≥3, would be expected in these populations.
To compare our results with those in 1000 Genomes Project, we endeavored to analyze the data from the
database [37], using NCBI Genome Browser for GRCh37.p13 [38]. The data confirmed population genetics and
frequency distribution of TPMT*3C and TPMT*3A alleles, and complete LD between TPMT*3C and TPMT*3B
alleles. Individuals with TPMT*3 alleles were further analyzed for the VNTR pattern. The coverage of this region,
surrounding nucleotide 18,155,419 (Chr 6), was very low or nonexistent, which in the majority of cases made it
impossible to identify these long and complex VNTR polymorphisms lying within a G/C-rich region in the TPMT
promoter. Nevertheless, in approximately 20% of TPMT*3 individuals the VNTR pattern in the TPMT promoter
could be partially predicted with the sequence pointing toward AB- and not AA- pattern, which is in line with our
study, where patterns with single A and several B VNTR motifs occur in individuals carrying TPMT*3 allele. .
Despite the great advances of the next-generation sequencing, it has been previously reported, that genome assembly
for highly G/C-rich regions is challenging and results in reduced or no coverage [39]. Alternative approaches in
sequencing complete VNTR assemblies such as single molecule real time sequencing have the potential to facilitate
future high throughput studies of such polymorphisms [40].
Conclusion
We report a novel VNTR pattern AB7C, which was observed in a TPMT*1/*3A individual. Furthermore, our
findings provide novel insights into the concurrent development of VNTR and TPMT*3 alleles. We confirmed
that TPMT*3 alleles correlate with TPMT activity. However, we could not conclude what influence (if any)
VNTR polymorphisms have on the activity of the enzyme, since patterns with ABnC, n ≥2, are in significant LD
with TPMT*3 alleles. Our study suggests that VNTR pattern AB2C is associated with TPMT*3C, while patterns
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ABnC, n≥3, are associated with TPMT*3A allele, suggesting these VNTR sequences as indirect pharmacogenomic
markers.
Future perspective
Based on the present results, it is possible that the VNTR region has no influence on the TPMT activity and that
the previously observed association is the sole consequence of the linkage between ABnC, n≥2, VNTR motifs and
TPMT*3 alleles. Conversely, the same results could indicate the joint influence of the VNTR region and TPMT*3
alleles on the enzyme activity. Interesting insights in function of TPMT promoter region have been previously
reported in terms of TPMT expression and binding of transcription factors [10,16,41]; however, the role of VNTR
in the promoter region of TPMT remains unresolved. Further functional in vitro studies are necessary to decipher
the possible influence of the VNTR region on TPMT activity.
Based on its sequence, the B motif is strongly indicated as predicted binding site for transcription factor Sp1,
which is a recognized regulator of TPMT transcription [16,41]. At the same time, sequence of motif B carries
determinants that enable formation of G-quadruplexes [42]. Even though their formation in promoter of TPMT has
not been investigated, G-quadruplexes can be envisaged as regulators of VNTR stability or an element that directs
transcription of the gene. In light of our findings, future studies of such secondary structures would be extremely
important, since multiple B motifs are present in the promoter regions of TPMT*3 alleles. They might be even
assumed as regulatory domains counteracting TPMT-activity-lowering SNPs in coding region of the TPMT.
Summary points
• We report a novel pattern of variable number of tandem repeats (VNTR) in the TPMT promoter: AB7C.
• Only TPMT*3A individuals carried one of the following VNTR alleles: AB3C, AB4C, AB5C and AB7C.
• Only TPMT*3C individuals carried AB2C allele.
• VNTR patterns with single A and multiple B motifs are associated with TPMT*3 alleles. VNTR patterns with three
or more B motifs developed concurrently with the TPMT*3B SNP from pattern AB2C, which coexisted with the
TPMT*3C allele.
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